{"id":"plk1","name":"PLK1","symbol":"PLK1","route":"/targets/plk1/","asOf":"2026-09-23","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9077","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166851","uniprot":"https://www.uniprot.org/uniprotkb/P53350/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P53350","open-targets":"https://platform.opentargets.org/target/ENSG00000166851","civic":"https://civicdb.org/genes/5347/summary","oncokb":"https://www.oncokb.org/gene/PLK1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PLK1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=PLK1","depmap":"https://depmap.org/portal/gene/PLK1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000166851-PLK1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5347","omim":"https://www.omim.org/entry/602098"}],"products":[{"id":"onvansertib","name":"Onvansertib","status":"phase-2","modality":"Oral serine/threonine kinase inhibitor","route":"/drugs/onvansertib/"}],"trials":[{"id":"nct06106308","name":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo","nct":"NCT06106308","phase":"2","status":"active"},{"id":"nct05450965","name":"Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer","nct":"NCT05450965","phase":"2","status":"recruiting"},{"id":"nct06736717","name":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","nct":"NCT06736717","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["cardiff-oncology"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}